Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.
Pfizer inks $11.4B Array cancer deal
Pfizer has agreed to buy Array BioPharma for $11.4 billion
Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it's betting on oncology.
In the first big M&A deal under new CEO Albert Bourla, Pfizer has agreed to buy oncology specialist Array BioPharma for a total value of about $11.4 billion, the two companies unveiled Monday. The $48-per-share offer represents a premium of about 62% to Array stock’s closing price on Friday.
With the acquisition, Pfizer will beef up its oncology offerings with two marketed drugs, MEK inhibitor Mektovi and BRAF inhibitor Braftovi, which are approved as a combo treatment for melanoma and recently turned up positive results in colon cancer. The buy will enhance the Pfizer innovative drug business’ “long-term growth trajectory,” Bourla said in a Monday statement, dubbing Mektovi-Braftovi “a potentially industry-leading franchise for colorectal cancer.”
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
M&A TRANSACTIONS
Pharma & Biotech
17 transactions totaling $1,179 million
Supplies, Equipment & Services
30 transactions totaling $512 million
Healthcare IT & Managed Care
2 transactions
Healthcare Facilities & Distributors
6 transactions totaling $16 million
PRIVATE PLACEMENTS
Pharma & Biotech
29 transactions totaling $354 million
Supplies, Equipment & Services
13 transactions totaling $241 million
Healthcare IT & Managed Care
15 transactions totaling $160 million
Healthcare Facilities & Distributors
1 transaction
PUBLIC OFFERINGS
Pharma & Biotech
14 transactions totaling $300 million
Supplies, Equipment & Services
2 transactions totaling $10 million
Healthcare IT & Managed Care
0 transactions
Healthcare Facilities & Distributors
0 transactions
INDUSTRY TRADING COMPS
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.
For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table.
Note: data reflects prior week close.
RECENT INDUSTRY TRANSACTIONS
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
The report, from the business research and consulting firm Roots Analysis, examined approximately 140 companies offering patient recruitment and retention services. Per the report, the market is fragmented with a mix of small (69%), mid (14%), and large-sized (17%) companies.
Catalent has been on a buying spree, adding biologics and gene therapy capabilities to its manufacturing repertoire as most drug development moves in those directions. In a deal announced today, it is buying a site in Italy from Bristol-Myers Squibb that handles biologics but also has a long history with old-school solid dose production.
The French drug maker has joined forces with Google to create a new virtual innovation lab, where the partners will marry Google's technology and analytics expertise with Sanofi's data to bring deeper understanding of diseases and patients' experience.
MARKET REPORTS
Recent Materials Providing Insight Into Healthcare Related Industries
